期刊文献+

MMP-2、MMP-9在胃肠道间质瘤中的表达及其临床意义 被引量:3

Clinical significance of MMP-2、MMP-9 expression in gastrointestinal stromal tumor
下载PDF
导出
摘要 目的:探讨基质金属蛋白酶(MMP)-2、MMP-9在胃肠道间质瘤(GIST)中的表达及其与预后的关系。方法:采用免疫组化方法检测54例GIST组织中的MMP-2、MMP-9的表达,分析与各病理参数的关系。结果:肿瘤组织中的MMP-2、MMP-9阳性率分别为85.2%、83.3%,并随着GIST恶性程度的增高,其表达均出现递增趋势,差异有显著性意义(P<0.05);与肿瘤良恶性、生长方式、肿瘤大小、肿瘤中心有无坏死亦有明显关系(P<0.01)。单因素分析MMP-2、MMP-9阳性表达的患者有较高的5年生存率,多因素分析发现MMP-2、MMP-9共表达能独立预测患者的5年生存率。结论:MMP-2、MMP-9在GIST中的表达率可以作为判断GIST性质、恶性程度、转移及预后的客观指标。 Objectives: To evaluate the clinical significance of MMP-2, MMP-9 expression in gastrointestinal stromal tumor. Methods: 54 of GIST were studied for MMP-2, MMP-9 by immunohistochemical staining, and the relationship of MMP-2, MMP-9 with each pathological factor were analyzed. Results:The positive expression of MMP-2, MMP-9 was 85.2% (46/54), 83.3% (43/54) respectively. The expression of MMP-2, MMP-9 increased significantly according to the malignant increasing (P〈0.01) and associated with pattern of tumor growing, tumor size, and centre necrosis (P〈0,01). In univariate analysis, MMP-2, MMP-9 were significantly associated with tumorfree survival. In multi-variate analysis, co-expression of MMP-2 and MMP-9 was unfavorablely related with tumor free survival (RR=2.487: P〈0.05). Conclusion: Over-expression of MMP-2 and MMP-9 in GIST judge the malignant degree and predicting the prognosis of patients with GIST.
出处 《中国现代普通外科进展》 CAS 2007年第2期135-137,共3页 Chinese Journal of Current Advances in General Surgery
关键词 胃肠道间质瘤 基质金属蛋白酶 Gastrointestinal stromal tumor, Marix metalloproteinases
  • 相关文献

参考文献6

二级参考文献11

共引文献16

同被引文献32

  • 1宁建文,季峰,王丽君,许国强,厉有名.265例胃肠道间叶源性肿瘤的临床病理特征及超声内镜诊断价值[J].中华消化杂志,2006,26(6):381-385. 被引量:37
  • 2汪露祥,吴强,丁向东,杨枫,蒋振,吴献忠.MMP-9、TIMP-1及MMP-2、TIMP-2表达与胃肠道间质瘤生物学行为的关系[J].中国基层医药,2006,13(6):928-930. 被引量:5
  • 3Singer S,Rubin BP,Lux ML,et al.Prognostic value of KIT mutation type,mitotic activity,and histologic subtype in gastrointestinal stromal tumors[J].Clin Oncol,2002,20(3):898-905.
  • 4Dirnhofer S,Leyvraz S.Current standards and progress in understanding and treatment of GIST[J].Swiss Med Wkly,2009,139(7-8):90-102.
  • 5Tsukuda K,Hirai R,Miyake T,et al.The outcome of gastrointestinal stromal tumors (GISTs) after a surgical resection in our institute[J].Surgery today,2007,37:953-957.
  • 6Mazur MT,Clark HB,Gastric stromal tumors:reappraisal of histogenesis[J].Am J Surg Pathol,1983,7(6):507-519.
  • 7Hirota S,Isozaki K,Moriyama Y,et al.Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-580.
  • 8Nilsson BP,Bumming P,Meis-Kindblom JM,et al.Gastrointestinal stromal tumors:The incidence,prevalence,clinical course,and prognostication in the preimatinib mesylate era[J].Cancer 2005,103:821-829.
  • 9Shah P,Gao F,Edmundowicz SA,et al.Predicting Malignant Potential of Gastrointestinal Stromal Tumors Using Endoscopic Ultrasound[J].Dig Dis Sci,2009,54:1265-1269.
  • 10Jamali F,Darwiche S,El-Kinge N,et al.Disease progression following imatinib failure in gastrointestinal stromal tumors:Role of surgical therapy[J].The Ongologist,2007,12:438-442.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部